Founded in 2017, Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy's lead offering, the ATX-Gx platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/21 | $75,000,000 | Series C |
Alexandria Venture Investments Founders Fund Gaingels Luma Bio-IT Mubadala Capital Peter Thiel  Presight Captial Ulysses Holdings | undisclosed |
